Company Enters Growth Phase in Hospital Market with Support of Deerfield Acquisition to Augment Company’s Core Antibiotic Portfolio MORRISTOWN, N. J. , June 09, 2020 (GLOBE NEWSWIRE) — Melinta Therapeutics, Inc. (“Melinta”), a commercial-stage antibiotics company, announced that on June 4, 2020, it entered into a definitive merger agreement with Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) pursuant...
Category: News
Amplyx Pharmaceuticals Expands Executive Leadership Team
Appoints Chris LeMasters as Chief Operating Officer and Carlos Sattler, M.D., as Senior Vice President, Clinical Development SAN DIEGO – June 3, 2020 – Amplyx Pharmaceuticals, a clinical-stage biopharmaceutical company developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, today announced the appointment of Chris LeMasters to the position of chief operating officer and...
SCYNEXIS to Present at the BIO Digital International Convention 2020
SCYNEXIS to Present at the BIO Digital International Convention 2020 Company presentation will highlight progress towards transitioning to a fully integrated commercial stage company with an initial focus on vaginal yeast infection JERSEY CITY, N.J., June 08, 2020 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering...
Summit Appoints Michael Donaldson as Chief Financial Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Michael Donaldson as Chief Financial Officer Oxford, UK, and Cambridge, MA, US, June 8, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance...
Summit Appoints Michael Donaldson as Chief Financial Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Michael Donaldson as Chief Financial Officer Oxford, UK, and Cambridge, MA, US, June 8, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance...
Summit Appoints Michael Donaldson as Chief Financial Officer
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Appoints Michael Donaldson as Chief Financial Officer Oxford, UK, and Cambridge, MA, US, June 8, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today announces that Mr. Michael Donaldson has been appointed as Chief Financial Officer, effective immediately. Mr. Donaldson brings to Summit over 20 years of finance...
Iterum Therapeutics Announces $5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
DUBLIN, Ireland and CHICAGO, June 03, 2020 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has entered into definitive...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020 Oxford, UK, and Cambridge, MA, US, June 2, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results and provides an update on its operational conditions...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020 Oxford, UK, and Cambridge, MA, US, June 2, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results and provides an update on its operational conditions...
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter and Three Months Ended March 31, 2020 Oxford, UK, and Cambridge, MA, US, June 2, 2020 – Summit Therapeutics plc (NASDAQ: SMMT) today reports its financial results and provides an update on its operational conditions...